PRN/Stealth DRC An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects with Intermediate Age-Related Macular Degeneration

Administered By

Awarded By

Contributors

Start/End

  • November 29, 2016 - October 27, 2018